Structural and molecular basis for Ebola virus neutralization by protective human antibodies-Reference-Cited by-同舟云学术

Structural and molecular basis for Ebola virus neutralization by protective human antibodies

Published:2016-03-18 Issue:6279 Volume:351 Page:1343-1346
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Misasi John¹²³,Gilman Morgan S. A.⁴,Kanekiyo Masaru¹,Gui Miao⁵,Cagigi Alberto¹,Mulangu Sabue¹,Corti Davide⁶,Ledgerwood Julie E.¹,Lanzavecchia Antonio⁶⁷,Cunningham James²,Muyembe-Tamfun Jean Jacques⁸,Baxa Ulrich⁹,Graham Barney S.¹,Xiang Ye⁵,Sullivan Nancy J.¹,McLellan Jason S.⁴

Affiliation:

1. Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.

2. Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA.

3. Division of Infectious Diseases, Boston Children’s Hospital, Boston, MA 02215, USA.

4. Department of Biochemistry, Geisel School of Medicine at Dartmouth, Hanover, NH 03755, USA.

5. Centre for Infectious Diseases Research, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Beijing Advanced Innovation Center for Structural Biology, Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing 100084 China.

6. Institute for Research in Biomedicine, Università della Svizzera Italiana, CH-6500 Bellinzona, Switzerland.

7. Institute of Microbiology, ETH Zurich, CH-8093 Zurich, Switzerland.

8. National Institute for Biomedical Research, National Laboratory of Public Health, Kinshasa B.P. 1197, Democratic Republic of the Congo.

9. Electron Microscopy Laboratory, Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.

Abstract

Antibodies block Ebola virus entry The recent Ebola virus outbreak in West Africa illustrates the need for both an effective vaccine and therapies to treat infected individuals. Corti et al. isolated two monoclonal antibodies from a survivor of the 1995 Kikwit outbreak and demonstrated their therapeutic efficacy in Ebola virus–infected macaques. In fact, one antibody protected macaques when it was given up to 5 days after infection. Misasi et al. solved the crystal structures of fragments of the two antibodies bound to the Ebola virus glycoprotein (GP), which mediates viral cell entry. The two antibodies targeted different regions of GP, but in both cases blocked steps required for viral entry. Science , this issue pp. 1339 & 1343

Funder

Intramural Research Program of the Vaccine Research Center

National Institute of Allergy and Infectious Diseases

NIH

Boston Children's Hospital Faculty Development

National Institute of General Medical Sciences of the National Institutes of Health

973 program

National Natural Science Foundation of China

Junior Thousand Talents Program of China

Frederick National Laboratory for Cancer Research

National Institutes of Health

Publisher